The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction

Eitemau Tebyg

• The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
  gan: Barton, P, et al.
  Cyhoeddwyd: (2004)
• The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
  gan: Barton, P, et al.
  Cyhoeddwyd: (2004)
• The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
  gan: Jobanputra, P, et al.
  Cyhoeddwyd: (2002)
• The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
  gan: Jobanputra, P, et al.
  Cyhoeddwyd: (2002)
• Effects of treatment of rheumatoid arthritis patients with an antibody against tumour necrosis factor alpha on reticuloendothelial and intrapulmonary granulocyte traffic.
  gan: Taylor, P, et al.
  Cyhoeddwyd: (1999)